Recent Updates
Recently added Catalysts

Evaxion A/S

EVAXFDA catalysts, PDUFA dates & pipeline intelligence
$2.78
▲ +0.01 · +0.36%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full EVAX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.6552W HIGH $6.92
Volume
34.70 K
Value Traded
96.45 K
Short % Float
0.41%
Days to Cover
1.0
-4.47%Week
-16.52%1 Month
-11.75%3 Month
-30.5%6 Month
-98.88%5 Year
-99.18%All Time

Cash Data

Unlock EVAX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
25.08 M
EPS (TTM)
-1.38
P/E Ratio
-
Ent. Value
15.59 M
Total Shares
9.02 M
Float Shares
6.74 M
Insiders
19.22%
Institutions
6.74%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Pre-clinical data presentation
EVX-04 DNA vaccine
Acute myeloid leukemia (AML)
Pre-clinicalVaccinesOncology
Unlock every EVAX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

EVAX Catalyst Timeline

Dated clinical, regulatory and corporate events for Evaxion A/S

Catalyst Timeline

Dated clinical, regulatory & corporate events for Evaxion A/S

193Total events
12Upcoming
32Tier-1 (high impact)
2020 to 2027Coverage

Upcoming catalysts 2

T3Poster Presentation
Subscribe to view catalyst details
T3Poster Presentation
Subscribe to view catalyst details
EVX-04

Event history 50

●Equity OfferingCorporate
Evaxion files amendment to Form F-1 registration statement related to EIB warrant resale
●Poster PresentationEVX-01Presentation
Poster presentation of EVX-01 Phase 2 biomarker data at SITC 2026
advanced melanomasource ↗
●Oral PresentationEVX-01Presentation
Oral presentation of EVX-01 Phase 2 biomarker data at SITC 2026
advanced melanomasource ↗
▲Biomarker DataEVX-01Clinical Data
New biomarker data from Phase 2 EVX-01 trial showing ex vivo neoantigen-specific T-cell responses
advanced melanomasource ↗
▲Grant / FundingCorporate
Evaxion awarded 2026 International Prix Galien Award for AI-Immunology™ as best digital health solution
▲Poster PresentationEVX-01Presentation
Three-year immune and clinical data for EVX-01 presented in poster at ESMO 2026 Congress
advanced melanomasource ↗
▲Long Term DataEVX-01Clinical Data
Three-year follow-up data show 89% vaccine target precision and sustained T-cell and clinical responses
advanced melanomasource ↗
▲Long Term DataEVX-01Clinical Data
Three-year follow-up data from EVX-01 Phase 2 trial show sustained clinical responses in all patients
advanced melanomasource ↗
▲Oral PresentationEVX-01Presentation
Three-year Phase 2 data for EVX-01 presented at ESMO Congress in Madrid
advanced melanomasource ↗
▲Full ResultsEVX-01Clinical Data
Three-year Phase 2 data for EVX-01 in advanced melanoma presented at ESMO
advanced melanomasource ↗
Unlock the full EVAX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How EVAX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-06EVX-01 Phase 2 data presentation Phase 2
Unlock 5 more EVAX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 70%
Micro Cap
(rank 508 of 725)
Percentile Rank
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
EVX-01 VaccinesCompletedNCT05309421Melanoma Stage IVPhase 2 COMPLETED 17Apr 7, 2026
Unlock the EVAX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every EVAX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
EVX-01 advanced melanomaPhase 22026-11-0689%; three yearsRead MoreNew phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01Read More
Scroll for more · summaries link to the source press release
Unlock every EVAX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock EVAX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full EVAX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Ikarian Capital, LLC 0 % 245.01 K 74.70 K
Unlock every fund holding EVAX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in EVAX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see EVAX ownership
Insider and institutional ownership, quarter by quarter.

EVAX Short Interest

Shares sold short, counted twice a month.

0.41%
Short % of Float
of tradable shares sold short
27.6K
Shares Sold Short
-58.9% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
189.1K
Avg Daily Volume
the average used for days to cover
Unlock EVAX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock EVAX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live EVAX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock EVAX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How EVAX ranks across every disease it competes in

Competitive Position is a premium feature
See how EVAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

EVAX News

EVAX
Nov 12, 2026
EVAXGeneral

Evaxion announce 2027 financial calendar

Evaxion A/S has released its financial calendar for 2027, detailing key dates for business updates and financial results. Significant dates include the annual general meeting on April 29 and quarterly updates throughout the year. The company emphasizes its commitment to developing novel immunotherapies using its AI-Immunology platform.

Read more →
EVAX
Nov 9, 2026
EVAXGeneral
▼ -8.3%on this newsshared move

Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement

Evaxion A/S has filed an amendment to its registration statement regarding a debt settlement agreement with the European Investment Bank. This agreement, finalized in July 2025, converted €3.5 million of debt into equity through warrants. The amendment does not involve a capital raise, and Evaxion will not receive proceeds from any sales by the EIB.

Read more →
EVAX
Nov 6, 2026
EVAXPhases
▲ +5.6%on this newsshared move

New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

Evaxion A/S announced new biomarker data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The data shows strong immune responses and supports the predictive accuracy of the AI-Immunology platform. Notably, 89% of vaccine targets achieved tumor-specific immune responses, with sustained clinical responses observed over three years.

Read more →
EVAX
Nov 4, 2026
EVAXConferences/Events

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

Evaxion A/S will present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the ASH Annual Meeting in December 2026. The data support EVX-04's potential, showing broad patient coverage and effective T-cell responses. This builds on previous findings that demonstrated strong immune responses and tumor growth inhibition in preclinical models.

Read more →
EVAX
Nov 3, 2026
EVAXConferences/Events

Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion A/S will present new biomarker data from its phase 2 trial of EVX-01 at the SITC 2026 Annual Meeting. The trial showed a 75% objective response rate in advanced melanoma patients, with four achieving complete responses. The data will be shared in both oral and poster sessions during the event in Phoenix, Arizona.

Read more →
EVAX
Oct 30, 2026
EVAXGeneral

Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

Evaxion A/S has been awarded the 2026 International Prix Galien Award for its AI-Immunology™ platform, recognized as the best digital health solution. This marks the first time a Danish company has received this prestigious award. The platform is designed to enhance immunotherapy development for cancer and other diseases.

Read more →
EVAX
Oct 23, 2026
EVAXPhases

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion announced promising three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The results showed 89% of vaccine neoantigens elicited strong T-cell responses, with no tumor progression in patients. This data will be presented at the ESMO Congress 2026, highlighting the durability of clinical responses.

Read more →
EVAX
Oct 19, 2026
EVAXPhases
▲ +17.7%on this news· ran to +43% by day 1

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S announced promising three-year follow-up data from its phase 2 trial of the personalized cancer vaccine EVX-01 for advanced melanoma. All patients maintained their clinical responses, with no tumor progression observed. The results, showcasing a 75% Objective Response Rate, will be presented at the ESMO Congress 2026, highlighting the vaccine's potential in treating hard-to-treat cancers.

Read more →
EVAX
Oct 2, 2026
EVAXConferences/Events

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion A/S will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The data, derived from a phase 2 trial, highlights the vaccine's systemic immunomodulatory effects when combined with pembrolizumab in advanced melanoma patients. The findings will be shared through both oral and poster presentations.

Read more →
EVAX
Sep 14, 2026
EVAXPhases

Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Evaxion A/S is applying its AI-Immunology™ platform to develop treatments for autoimmune diseases, addressing a significant unmet medical need. The company is testing two novel concepts: a tolerogenic vaccine and an autoantibody binder. Initial data will be presented at the upcoming Protein & Antibody Engineering Summit in Lisbon on November 18, 2026.

Read more →
EVAX
Aug 20, 2026
EVAXGeneral

Evaxion announces business update and second quarter 2026 financial results

Evaxion A/S has provided a business update and financial results for Q2 2026, highlighting significant advancements in its R&D pipeline, including upcoming presentations of clinical data for its cancer vaccine candidates. The company has been recognized for its AI-Immunology platform, winning the 2026 Prix Galien UK Award. Despite a net loss of $3.7 million, Evaxion maintains a cash runway into the second half of 2027.

Read more →
EVAX
Aug 17, 2026
EVAXGeneral
▼ -6.3%on this newsshared move

Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program

Evaxion A/S has announced the expansion of its R&D pipeline with EVX-05, an AI-designed vaccine targeting glioblastoma. This off-the-shelf therapeutic vaccine aims to address the significant unmet medical needs in treating this aggressive brain cancer. The company is collaborating with Duke University for initial clinical testing, while maintaining a robust cash runway into 2027 despite discontinuing the EVX-03 program.

Read more →
EVAX
Aug 14, 2026
EVAXGeneral

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

Evaxion A/S will announce its business update and second quarter 2026 financial results on August 20, 2026. The company will host a conference call and webcast at 14:30 CET/08:30 EST to present the results and answer questions. Evaxion focuses on developing novel vaccines using its AI-Immunology platform, addressing significant medical needs.

Read more →
EVAX
Jul 17, 2026
EVAXConferences/Events

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Evaxion A/S will present three-year clinical efficacy data for its personalized cancer vaccine EVX-01 at the ESMO Congress 2026. This data, stemming from a phase 2 trial, will provide insights into the vaccine's effects as a stand-alone treatment for advanced melanoma. Previous two-year results showed a 75% objective response rate and significant durability of responses.

Read more →
EVAX
Jul 12, 2026
EVAXPhases

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion A/S presented promising preclinical data for its cytomegalovirus vaccine program EVX-V1 at the International Herpesvirus Workshop 2026. The data indicates that the vaccine could improve control of CMV infections through a multi-component approach that utilizes AI-discovered antigens. This advancement is crucial as CMV poses significant health risks, particularly to immunocompromised individuals and infants.

Read more →
EVAX
Jul 1, 2026
EVAXPhases

Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop

Evaxion A/S will present new preclinical data for its cytomegalovirus vaccine candidate, EVX-V1, at the International Herpesvirus Workshop in Montreal. The data will aid in the final selection of antigens for the vaccine, which combines novel AI-discovered and optimized components. This innovative approach aims to enhance the vaccine's protective potential against CMV.

Read more →
EVAX
Jun 12, 2026
EVAXGeneral

Evaxion receives Prix Galien UK Award for Best digital health solution

Evaxion A/S has been awarded the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology™ platform. This recognition highlights the platform's capabilities in developing novel vaccines for cancer and infectious diseases. The award was presented to CEO Helen Tayton-Martin at a ceremony in London, marking a significant achievement for the company.

Read more →
EVAX
Jun 11, 2026
EVAXPhases

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

Evaxion A/S has announced promising preclinical data for its therapeutic vaccine EVX-04, targeting acute myeloid leukemia (AML). The vaccine is shown to be effectively expressed and secreted in human cells, driving specific immune responses that mediate targeted cell-killing. This data will be presented at the EHA 2026 Congress, highlighting its potential as a novel treatment option for AML patients.

Read more →
EVAX
May 12, 2026
EVAXPhases

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress

Evaxion A/S will present new preclinical data for EVX-04, a therapeutic vaccine for acute myeloid leukemia (AML), at the EHA 2026 Congress in Stockholm. The data will focus on the functional characterization of EVX-04, which targets specific tumor antigens. The company plans to submit a clinical trial application later in 2026.

Read more →
EVAX
May 7, 2026
EVAXGeneral
▼ -7.7%on this newsshared move

Evaxion announces business update and first quarter 2026 financial results

Evaxion A/S reported a positive business update alongside its Q1 2026 financial results, highlighting significant advancements in its AI-Immunology™ platform. The company achieved an 86% vaccine target recognition rate for its personalized cancer vaccine, EVX-01, and successfully extended its phase 2 trial. Additionally, Evaxion is developing new polio vaccine concepts in collaboration with The Gates Foundation. Despite a net loss increase, the company maintains a cash runway into 2027.

Read more →

About Evaxion A/S

46 employees evaxion.ai
BIOPHARMAWATCH ELITE
Trade the next EVAX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime